Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Deciphera Pharmaceuticals, Inc. (DCPH)  
$25.36 0.01 (0.04%) as of 4:30 Fri 5/10


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 60,930,000
Market Cap: 1.55(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $10.11 - $25.38
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. In addition, Co. has identified and developed various product candidates from its platform into clinical studies, including vimseltinib and DCC-3116. Co. is studying vimseltinib in a Phase 3 study in patients with tenosynovial giant cell tumor. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 10,000 1,687,666
Total Buy Value $0 $0 $138,828 $30,291,232
Total People Bought 0 0 1 3
Total Buy Transactions 0 0 1 3
Total Shares Sold 10,159 75,715 115,161 179,650
Total Sell Value $158,659 $1,108,986 $1,602,723 $2,646,007
Total People Sold 4 5 6 6
Total Sell Transactions 4 14 25 43
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 290
  Page 9 of 12  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-12-09 4 AS $55.00 $1,659,625 D/D (30,175) 24,500     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-12-09 4 OE $1.89 $57,031 D/D 30,175 54,675     -
   Morl Christopher John Chief Business Officer   •       –      –    2019-12-09 4 AS $55.00 $186,285 D/D (3,387) 0     -
   Morl Christopher John Chief Business Officer   •       –      –    2019-12-09 4 OE $3.95 $13,379 D/D 3,387 3,387     -
   Morl Christopher John Chief Business Officer   •       –      –    2019-12-03 4 AS $50.00 $751,763 D/D (15,034) 0     -
   Morl Christopher John Chief Business Officer   •       –      –    2019-12-03 4 OE $0.00 $0 D/D 15,034 15,034     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-11-11 4 AS $48.01 $6,874,870 D/D (143,185) 24,500     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-11-11 4 OE $1.89 $270,620 D/D 143,185 167,685     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-11-08 4 AS $48.00 $467,616 D/D (9,742) 24,500     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-11-08 4 OE $1.89 $18,412 D/D 9,742 34,242     -
   Bristol James Arthur Director   –       •      –    2019-11-01 4 AS $45.07 $1,126,823 D/D (25,000) 0     -
   Bristol James Arthur Director   –       •      –    2019-11-01 4 OE $1.89 $47,250 D/D 25,000 25,000     -
   Taylor Michael Douglas Director   –       •      –    2019-11-01 4 AS $45.02 $337,646 D/D (7,500) 0     -
   Taylor Michael Douglas Director   –       •      –    2019-11-01 4 OE $1.89 $14,175 D/D 7,500 7,500     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-10-28 4 AS $40.00 $1,192,800 D/D (29,820) 24,500     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-10-28 4 OE $1.89 $56,360 D/D 29,820 54,320     -
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2019-10-28 4 AS $40.00 $150,010 D/D (3,750) 0     -
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2019-10-28 4 OE $1.89 $7,088 D/D 3,750 3,750     -
   Sherman Matthew L EVP & Chief Medical Officer   •       –      –    2019-10-15 4 A $0.00 $0 D/D 35,000 35,000     -
   Martin Daniel C. Chief Commercial Officer   •       –      –    2019-09-19 4 AS $35.56 $106,688 D/D (3,000) 17,000     -
   Taylor Michael Douglas Director   –       •      –    2019-09-11 4 AS $34.81 $786,832 D/D (22,500) 0     -
   Taylor Michael Douglas Director   –       •      –    2019-09-11 4 OE $1.89 $42,525 D/D 22,500 22,500     -
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2019-09-11 4 AS $34.80 $393,440 D/D (11,250) 0     -
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2019-09-11 4 OE $1.89 $21,263 D/D 11,250 11,250     -
   Taylor Michael Douglas Director   –       •      –    2019-09-03 4 AS $36.26 $271,975 D/D (7,500) 0     -
  290 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 9 of 12
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us